Evidence map›Paper›PMID 36075011›Full record

ArticleJCO precision oncology2022

Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.

Julia Schiantarelli, Theodora Pappa, Jake Conway, Jett Crowdis, Brendan Reardon, Felix Dietlein, Julian Huang, Darren Stanizzi, Evan Carey, Alice Bosma-Moody and 11 more

Open access · greenAbstract read
In one paragraph

Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Disentangling sources of clock-like mutations in germline and soma.bioRxiv : the preprint server for biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Julia SchiantarelliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-5705-1309
Theodora PappaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jake ConwayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-6617-2054
Jett CrowdisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-4777-7303
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-1716-5720
Felix DietleinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-6651-7155
Julian HuangYale School of Medicine, New Haven, CT.
Darren StanizziDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Evan CareyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-2487-2968
Alice Bosma-MoodyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Alma ImamovicDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-4454-6868
Seunghun HanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-0235-7252
Sabrina CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9695-5527
Eric KofmanDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.ORCID 0000-0001-5462-9099
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Justine A BarlettaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-8622-7470
David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-0346-5033
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4451-2046
Jochen H LorchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-0201-4444
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USNorthwestern University · USUniversity of California San Diego · USYale University · US

Funding

MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
TRAINING PROGRAM IN HYPERTENSIONT32HL007609 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 1985 to 2022
$10.2M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
A pan-cancer atlas of driver mutations in >100,000 patients based on a hypothesis-driven combined computational and experimental approachK99CA262152 · NCI · DANA-FARBER CANCER INST · PI DIETLEIN, FELIX · 2021 to 2021
$133k
Redefining the Molecular Landscape of MelanomaF31CA239347 · NCI · HARVARD MEDICAL SCHOOL · PI CONWAY, JAKE · 2019 to 2021
$100k
NCI NIH HHS F31 CA239347NCI NIH HHS K99 CA262152NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA222574NHLBI NIH HHS T32 HL007609NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Ovarian NeoplasmsThyroid NeoplasmsCarboplatinFemaleHumansPlatinumCarboplatinPlatinum

Identifiers

PMID36075011
PMCPMC9489159
OpenAlexW4294975888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.